New Leadership Brings Strength in Science and Engineering

LANCASTER, Calif.–Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software to the pharmaceutical industry, announces the appointment of Mr. John DiBella as manager of marketing and sales, reporting to Dr. Michael Pelekis, director of business development, marketing, and sales.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “Mr. Ronald Creeley, former vice president of marketing and sales, has resigned as of the end of this month. Mr. DiBella has been with Simulations Plus for over six years, four of those in marketing and sales, and has done an outstanding job in demonstrating the products as well as the more difficult task of training new users in how to get the most from them. John holds a master’s degree in biomedical engineering from Case Western Reserve University. He was the original developer of our DDDPlus™ simulation software program, the only program available for simulating in vitro dissolution experiments. John’s strong engineering and science background, in-depth knowledge of our products and services, and business acumen developed from more than four years in sales, bring a new dimension to the leadership of our marketing and sales efforts.”

Mr. DiBella added: “I’m excited to have this opportunity to lead our marketing and sales efforts. After the transition from developing our DDDPlus simulation software product, I wanted to work more in direct customer contact. Simulations Plus gave me the opportunity to move into marketing and sales, becoming the company’s first full-time salesperson, and I have enjoyed it thoroughly. Simulations Plus is in an enviable position with best-in-class products and an outstanding reputation for good science and excellent software. I look forward to working with the rest of the talented Simulations Plus staff to increase our market penetration and growth rate.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company’s Words+ subsidiary, which provides assistive technology for persons with disabilities as well as two retail products, Abbreviate! (recently introduced as a new application for the iPhone) and FutureLab™, comprise the remainder of the business. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: the ability of the Company to maintain its competitive advantage, the general economics of the pharmaceutical and assistive technology industries, the ability of the Company to attract and retain sufficient scientific and technical staff to sustain its R&D and customer support functions, the continued high renewal rate for the Company’s software licenses, and a sustainable market. Further information on the Company’s risk factors is contained in the Company’s quarterly and annual reports as filed with the Securities and Exchange Commission.